SCHEMBL23293168

SCHEMBL23293168

CCOC(=O)c1nc(C)ccc1NC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 2/20 0.45
RAB9A P51151 2/20 0.44
BRD4 O60885 1/20 0.44
THRB P10828 1/20 0.44
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA12 O43570 1/20 0.42
ESR1 P03372 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
ESR2 Q92731 1/20 0.42
CA14 Q9ULX7 1/20 0.42
POLB P06746 1/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TARBP2 Q15633 1/20 0.41
SLC2A1 P11166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30616700 1.00 MEN1 (0.45) MEN1KMT2ACYP1A2RAB9ABRD4
SCHEMBL19372549 0.84 TARBP2 (0.44) MEN1KMT2ACYP1A2RAB9ABRD4
SCHEMBL13348774 0.81 TSHR (0.56) MEN1KMT2ACYP1A2RAB9ABRD4
SCHEMBL25389928 0.81 BRD4 (0.49) MEN1KMT2ACYP1A2RAB9ABRD4
SCHEMBL31288369 0.81 BRD4 (0.49) MEN1KMT2ACYP1A2RAB9ABRD4
SCHEMBL13406205 0.80 KDM4E (0.50) MEN1KMT2ACYP1A2CA1CA2
SCHEMBL4908993 0.79 BRD4 (0.44) MEN1KMT2ACYP1A2RAB9ABRD4
SCHEMBL2160799 0.79 PDE10A (0.49) MEN1KMT2ARAB9ATHRBKDM4E
SCHEMBL9308330 0.78 TSHR (0.53) MEN1KMT2ACYP1A2CA1CA2
SCHEMBL14191231 0.78 PRKCI (0.41) RAB9AKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866430-B2 Naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 US disclosed
CN-112585139-B Naphthyridinone compounds as T cell activators 百时美施贵宝公司 2023-12-01 CN disclosed
EP-3814347-B1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-03 EP disclosed
EP-3814347-B1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-03 EP disclosed
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2021-09-09 US disclosed
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2021-09-09 US disclosed
EP-3814347-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 EP disclosed
CN-112585139-A Nalidinone compounds as T cell activators 百时美施贵宝公司 2021-03-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866430-B2 Naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG MEN1 2238/4885KMT2A 1903/4885CYP1A2 4346/4885
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG MEN1 2238/4885KMT2A 1903/4885CYP1A2 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.